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Background. Acute pancreatitis is the major complication of endoscopic retrograde cholangiopancreatography (ERCP) procedure
and there are some reports showing cytokine changes in ERCP-induced pancreatits. Goals. To investigate the association between
early changes (within 24 hours) in the serum interleukin (IL)-2, IL-4, tumor necrosis factor (TNF)α, and IL-6 levels and the
development of post-ERCP pancreatitis. Study. Forty ﬁve consecutive patients who underwent therapeutic ERCP and 10 patients
with acute pancreatitis without ERCP were enrolled to the study. Serum concentrations of IL-2, IL-4, TNFα,a n dI L - 6w e r e
determined immediately before, 12 hours and 24 hours after ERCP. Results. Seven of the 45 patients (15.5%) developed post-ERCP
pancreatitis. The levels of IL-4 at 24 hours after ERCP were signiﬁcantly lower in the patients with post-ERCP pancreatitis than
in those without pancreatitis, while TNFα levels at 12 hours after ERCP were higher in the complicated group than those of the
uncomplicated group. The ratios of TNFα/IL-4 at 12 and 24 hours after ERCP were found signiﬁcantly higher in the patients with
post-ERCP pancreatitis than in those without pancreatitis. IL-6 in the complicated patients was found signiﬁcantly increased at 24
hours after ERCP. Conclusions. The enhancement of serum TNFα and IL-6 levels in the patients with ERCP-induced pancreatitis
reﬂects the inﬂammatory activity. Additionally, these cytokines together with IL-4 can be used in clinical laboratory monitoring
of ERCP.
Copyright © 2008 Guldem Kilciler et al. This is an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly
cited.
1. INTRODUCTION
Acute pancreatitis is an important and critical complication
of endoscopic retrograde cholangiopancreatography (ERCP)
[1]. The incidence of post-ERCP pancreatitis has been
reported between 1% and 10% in various publications [2].
ERCP is mostly performed on an outpatient base. Therefore,
early diagnosis of post-ERCP pancreatitis is important for
hospital admission and management. However, recognition
of post-ERCP pancreatitis based on clinical datas is not
reliable [3]. Several biochemical and immunologic markers
were determined as predictor of pancreatic inﬂammation
after ERCP [4]. These markers are serum/urine amylase,
trypsinogen, trypsinogen activation peptide, C-reactive pro-
tein (CRP), and some cytokines [2, 4].
The studies show that the serum levels of tumor necro-
sis factor α (TNFα), interleukin (IL)-1β, IL-6, and IL-8
are signiﬁcantly increased in acute pancreatitis [2, 4, 5].
Pancreatic injury is mediated by the release of these proin-
ﬂammatory cytokines. After trypsinogen activation into
trypsin, a local inﬂammation is initiated which results in
the local production of inﬂammatory mediators [5]. Inter-
estingly, serum levels of anti-inﬂammatory molecules such
as IL-10, IL-1β receptor antagonist, and soluble IL-2
receptor (sIL-2r) were also found signiﬁcantly higher in
patientswithacutepancreatitis[4,5].Theseﬁndingssupport2 Clinical and Developmental Immunology
that these opposite eﬀective cytokines play roles together in
the pathogenesis of acute pancreatitis.
A dynamic balance exists between proinﬂammatory
(pro-) and anti-inﬂammatory cytokines. The timing of cy-
tokine release, the local milieu, the presence of antagonis-
tic or synergistic factors, and the cytokine receptor density
determines the net eﬀect of any cytokine [6]. Polarization
of T helper (Th) lymphocytes into functional Th1 and Th2
subsets is one of the main factors that determine the direc-
tion of the balance between pro- and anti-inﬂammatory
cytokines [7, 8]. While Th1 type cells produce high lev-
els of inﬂammatory cytokines including IL-2, TNFα,a n d
interferonγ (IFNγ), Th2 type cells produce anti-inﬂam-
matory cytokines including IL-4, IL-5, IL-6, IL-10, and
IL-13 [9]. Both type cells also produce lesser amounts
of TNFα, granulocyte-macrophage colonystimulating factor
(GM-CSF), and IL-3 [9]. Th1-type cytokines are essential
for the cell-mediated immune responses against intracel-
lular microorganisms [10]. However, Th2-type cytokines
participate in the development of humoral immunity against
extracellular microorganisms [10]. These 2-type cytokines
have cross-regulatory activity [9, 10]. IL-4 and IL-10 lead
to the inhibition of Th1-type immune responses by down-
regulating the production of macrophage-derived IL-12.
Whereas,IFNγ alteresthebalanceofTh1-/Th2-typeimmune
responses in favour of Th1 by suppressing the Th2-type
immune responses. It was also known that the imbalance
in the Th1/Th2 cytokine immune response is related to the
pathogenesis of some chronic inﬂammatory diseases such as
rheumatoid arthritis (RA), a Th1-type disease, and systemic
lupus erythematosus (SLE), a Th2-type disease [11].
The aim of this study was to investigate the association
between early changes (within 24 hours) in the serum IL-2,
IL-4, TNFα, and IL-6 concentrations and occurence of
subsequent pancreatitis complication after ERCP.
2. MATERIALS AND METHODS
Fortyﬁveconsecutivepatients(20menand25women;mean
age: 54.8 years; SD:15.9) who underwent therapeutic ERCP
wereenrolledtothestudy.Exclusionandinclusioncriteriaof
this study are detailed in Table 1. Control group consisted of
10patientswithacutepancreatitiswithoutERCP(7menand
3 women; mean age: 48.7 years; SD:17.3). Etiological factors
in the control group were gallstones in 4, drug useage in 3,
and alcohol in 2 patients. A certain etiological factor could
not be determined in 1 patient.
All the patients who underwent ERCP had normal
serum levels of CRP and amylase, before ERCP procedure.
Serum concentrations of IL-2, IL-4, TNFα,a n dI L - 6w e r e
determined immediately before 12 hours and 24 hours after
ERCP. ERCP was performed by the same operator after
premedication. Olympus JF-240 electronic duodenoscope
( O l y m p u sO p t i c a lC o . ,L t d ,T o k y o ,J a p a n )w a su s e df o r
ERCP. Radiologic images were taken by using C-arm x-
ray device (Philips, BV 300, Philips Medical Systems, Best,
The Netherlands). Antibiotic prophylaxis with Cephazolin
Sodiumwas started for all patients undergoing ERCP. After
an overnight fast, all patients were sedated with 10mg i.v.
dormicum.Forcytokinemeasurements,serumsamplesfrom
each patient were stored at −70◦C until run. However serum
amylase and CRP levels were determined on the day of sam-
pling. Serum amylase levels were determined by enzymatic
color test and upper limit of normal range was accepted as
90L/U according to our laboratory standarts. Serum CRP
levels were measured using a nephelometer (Behring BN II
Analyzer, Dade Behring, Marburg, Germany) and the high-
sensitivity reagent kit. A level <6mg/L for CRP was accepted
as normal. Serum levels of IL-2, IL-4, TNFα,a n dI L - 6w e r e
determined using ELISA kits (Bender MedSystems GmbH,
Vienna, Austria). Interassay and intra-assay coeﬃcients of
variation for each assay were, respectively, as follows: 8 and
5.2% for IL-2; 5.6 and 4.8% for IL-4; 7.4 and 6.9% for TNFα;
and 5.2 and 3.4% for IL-6.
The diagnostic criteria for post-ERCP pancreatitis were
epigastric pain during 24 hours after ERCP, at least three-
fold increase in upper limit of normal level of serum amylase
and/or acute pancreatitis seen in the abdominal ultrasonog-
raphy and computed tomography [12]. All patients were
informed about the aim and procedures of the study and
gave their consent. The study was approved by the Ethical
Committee of Gulhane Military School of Medicine.
All statistical analyses were performed using SPSS (SPSS
11.5, SPSS Inc., Chicago, IL, USA) statistical package. For
the tests of normality, we used Kolmogorov-Smirnov test.
Results are expressed as median (range). The Friedman test
was used for multiple statistical comparisons. The Wilcoxon
test was used as a post hoc test if the Friedman test is sta-
tistically signiﬁcant. Mann-Whitney U test was used to
compare the mean or median values of cytokines, CRP, and
amylase in blood in the various study groups. To investigate
the relations among the variables, we used Pearson or
Spearman’s rank correlation test, which was appropriate. A
P value < .05 was considered to be statistically signiﬁcant.
3. RESULTS
Seven of the 45 patients (15.5%) developed post-ERCP
pancreatitis. Two of them had severe pancreatitis and 5
patients had mild disease according to Atlanta criteria [13].
Firstsymptomswereoccuredameanof5.2hoursafterERCP
in these 7 patients.
Serum amylase levels at 12 and 24 hours after ERCP
were signiﬁcantly higher in the patients with post-ERCP
pancreatitis than in those without pancreatitis (Table 2). The
levels of amylase were also signiﬁcantly higher in the control
group with acute pancreatitis than in those of the levels
before and after ERCP in the patients without post-ERCP
pancreatitis. While serum amylase levels before and 24 hours
after ERCP were signiﬁcantly lower in the patients with post-
ERCP pancreatitis than those of the control group with acute
pancreatitis, the amylase levels at 12 hours after ERCP in
the patients with post-ERCP pancreatitis were not diﬀerent
from those of the control group with acute pancreatitis. CRP
levels before and within 24 hours after ERCP in the patients
who underwent ERCP and those of the control group with
acute pancreatitis were not diﬀerent from one other. In serial
measurements of complicated and uncomplicated patients,Guldem Kilciler et al. 3
Table 1: Exclusion and inclusion criteria of the patients.
Exclusion criteria Inclusion criteria
Emergency ERCP Choledocholithiasis
Previous therapeutic ERCP Pancreato-biliary
malignancy
Previous surgery of the upper GI tract Cholestasis of
unknown origin
Acute pancreatitis at time of study Cholangitis
Known history of chronic pancreatitis Tumor of papilla
Less than 18 years of age Others
Known history of mental disease
Unable to give informed consent
Female who is pregnant
Underlying chronic liver disease
Abnormal coagulation tests (PTT < 75%
or INR > 1.5 or APTT > 35)
Immunocompromized patients
serum amylase levels at 12 and 24 hours after ERCP were
higher than those of the basal levels (P = .018 and P < .001,
resp.), and the levels of amylase at 24 hours after ERCP were
also higher than those of the levels at 12 hours after ERCP
(P = .018 and P < .001, resp.). There was no signiﬁcant
diﬀerence among the CRP levels in the serial measurements
of complicated and uncomplicated patients.
Signiﬁcant diﬀerences in IL-4, IL-6 and TNFα levels at
12 and 24 hours after ERCP were found among the patients
who underwent ERCP and the control group patients. The
levels of IL-4 at 24 hours after ERCP in the patients with
post-ERCP pancreatitis and the control group patients were
signiﬁcantly lower than in those without ERCP-induced
pancreatitis (Table 2, Figure 1(a)). While TNFα levels in
the control group patients were higher than those of the
levels before ERCP in the patients with and without post-
ERCP pancreatitis (Table 2, Figure 1(b)), the levels of TNFα
at 12 hours after ERCP in the patients with and without
post-ERCP pancreatitis were not diﬀerent from the control
patients (Table 2, Figure 1(c)). However those TNFα levels
in the complicated group were higher than those of the
levels at 12 hours after ERCP in the uncompicated group
(Table 2, Figure 1(c)). There was no other signiﬁcant diﬀer-
ence among complicated and uncomplicated patients before
and within 24 hours after ERCP and control group patients
with respect to serum IL-4 and TNFα concentrations.
Addionally,IL-2levelsbeforeandwithin24hoursafterERCP
in the complicated and uncomplicated patients and the
control patients were not diﬀerent from one another. While
the levels of IL-6 were higher in the control group patients
than those of the levels before and 12 hours after ERCP in
both patients group who underwet ERCP (Table 2, Figures
1(d), 1(e)), IL-6 levels at 24 hours after ERCP in the patients
with post-ERCP pancreatitis were not diﬀerent from the
controlpatientsbuthigherthanthoseofthepatientswithout
post-ERCP pancreatits (Table 2, Figure 1(f)). On the other
hand, the ratios of TNFα/ I L - 4a t1 2a n d2 4h o u r sa f t e rE R C P
were found signiﬁcantly higher in the complicated patients
than those of the uncomplicated patients but not diﬀrent
from the control patients (Table 2, Figures 1(g), 1(h)). The-
re was not any diﬀerence with respect to IL-2/IL-4 ratio
among all patient groups.
Statistical signiﬁcant diﬀerences were observed among
the levels of IL-4, TNFα, and IL-6 in serial measurements
before and within 24 hours after ERCP in the patients
who underwent ERCP (Table 2, Figure 2). In the patients
with post-ERCP pancreatitis and without pancreatitis, sig-
niﬁcantly higher levels of TNFα and IL-6 were found at 12
hours after ERCP compared to the levels before ERCP. In the
patients without post-ERCP pancreatitis, the levels of IL-4,
TNFα, and IL-6 at 24 hours after ERCP were also higher than
those of the basal levels. However, in the complicated group,
only IL-6 levels at 24 hours after ERCP were higher than the
basal levels.
In the complicated patients, basal IL-6 levels positively
correlated with basal CRP levels, but negatively corre-
lated with basal IL-4 levels (r = 0.812; P = .048, r = 0.847;
P = .016, resp.). In the complicated patients, IL-4 and CRP
levels at 24 hours after ERCP were also negatively correlated
witheachother(r = 0.900;P = .037).Inthepatientswithout
post-ERCP pancreatitis, a positive correlation was found
between IL-4 and TNFα levels at 24 hours after ERCP
(r = 0.397; P = .018), but there was a negative correlation
between IL-4 and IL-6 levels at 12 hours after ERCP
(r = 0.392; P = .018).
4. DISCUSSION
Acute pancreatitis is the most common serious complication
of ERCP [1]. The incidence of post-ERCP pancreatitis was
found 15.5% in our study. This incidence is comparable to
that (2 to 15%) of other reports [14, 15].
In our study, serum amylase levels at 12 and 24 hours
after ERCP were signiﬁcantly higher in the patients with
post-ERCP pancreatitis than in those without pancreatitis.
Additionally, the levels of amylase were also signiﬁcantly
higher in the control group with acute pancreatitis than
in those of the levels before and 24 hours after ERCP and
those of the levels before and within 24 hours after ERCP
in the patients with post-ERCP pancreatitis and without
pancreatitis, respectively, but not diﬀerent from those of
the levels 12 hours after ERCP in the complicated group.
Hyperamylasemia associated with abdominal pain has been
evaluated as a reliable indicator of post-ERCP pancreatitis
[16, 17]. However, serum amylase levels are commonly
elevated in uncomplicated ERCPs. Therefore, it seems that
serum amylase measurement alone is not a well indicator in
predictingthedevelopmentofpancreatitisafterERCP.Inour
study, increased amylase levels at 12 and 24 hours after ERCP
were found in serial measurements of patients with post-
ERCP pancreatitis and without pancreatitis compared to the
basal levels. The levels of amylase at 24 hours after ERCP
in both patient groups were also higher than those of the
levels at 12 hours after ERCP. The serial changes of amylase
levels in patients without pancreatitis suggest the existance
of subclinical pancreatic damage. It is well known that serum4 Clinical and Developmental Immunology
Table 2: Comparisons of IL-2, IL-4, TNFα, IL-6, CRP and amylase levels and IL-2/IL-4 and TNFα/IL-4 ratios in the patients who underwent
ERCP and control group with acute pancreatitis without ERCP.
Patients with post-ERCP pancreatitis (n = 7) (1) Patients without pancreatitis (n = 38) (0)
Patients with acute
pancreatitis without
ERCP (n = 10) (2)
Time (hour) 0. 12. 24. 0. 12. 24.
IL-2 (pg/mL) 15.6 (19.9) 14.3 (14.1) 12.7 (15.5) 15.1 (43.9) 12.7 (76.0) 15.1 (46.0) 11.4 (13.0)
IL-4 (pg/mL) 29.0 (69.1) 63.6 (67.5) 37.7 (56.4)(a) 37.7 (146.8) 55.9 (83.8) 63.6 (98.0)(b) 37.9 (58.4)(c)
TNFα (pg/mL) 20.2 (67.8) 82.9 (81.9)(f) 44.9 (77.5) 18.6 (66.9)(d) 43.6(90.5)(g) 51.8 (72.1) 50.3 (77.5)(e)
IL-6 (pg/mL) 1.2(1.4)(h) 2.4 (1.9)(k) 3.4 (6.4)(m) 1.6 (5.8)(j) 2.4(10.5)(l) 1.9(7.3)(n) 5.2 (9.8)(i)
IL-2/IL-4 0.62 (2.03) 0.33 (2.30) 0.40 (0.90) 0.44 (26.81) 0.24 (2.61) 0.23 (0.71) 0.3 (0.61)
TNFα/IL-4 0.56 (10.0) 1.31 (5.77)(o) 1.18 (2.80)(r) 0.67 (91.83) 0.82(3.38)(p) 0.81 (1.35)(s) 1.0 (1.53)
CRP (mg/dL) 10.2 (49) 17.0 (33) 10 (47) 3.9 (212) 8.0 (395) 6.7 (342) 12.0 (42)
Amylase (U/mL) 50(74)(t) 1114 (1806)(x) 460 (552)(z) 47 (179)(v) 131(673)(y) 79(290)(zz) 1357 (2558)(u)
P values: .010 for (a) versus (b); .025 for (b) versus (c); .002 for (d) versus (e); .011 for (f) versus (g); .001 for (h) versus (i); <.001 for (j) versus (i); .014 for
(k) versus (i); .012 for (l) versus (i); .034 for (m) versus (n); .001 for (n) versus (i); .028 for (o) versus (p); .041 for (r) versus (s); .001 for (t) versus (u); <.001
for (v) versus (u); <.001 for (x) versus (y); <.001 for (y) versus (u); <.001 for (z) versus (zz); <.001 for (zz) versus (u); .001 for (z) versus (u).
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Figure 1: The levels of IL-4 (a) and TNF (b), (c), IL-6 (d), (e), (f) and the ratios of TNF/IL-4 (g), (h) in the patients with ERCP-induced
pancreatitis (EIP+), patients without ERCP induced pancreatitis (EIP−), and the control group (CG) with acute pancreatitis without ERCP.
Boxes show the ranges of 1st and 3rd quartiles and extreme values. Horizontal bars represent median values. The diﬀerences between two
groups were evaluated by Mann-Whitney U test. P values were indicated above the boxes when a level of signiﬁcance less than or equal to
.05 was reached in comparisons of study groups.
amylaselevelsriseinreactiontomanipulationsduringERCP
in the majority of patients [4].
C-reactive protein (CRP) is one of the acute-phase
reactantthatincreasesduringsystemicinﬂammation.Wedid
not ﬁnd any signiﬁcant diﬀerence in the levels of CRP before
and after ERCP in comparison between patients with post-
ERCP pancreatitis and without pancreatitis or among serial
measurements of complicated and uncomplicated patients.
C R Pl e v e l si nb o t hE R C Pgr o u p sw e r ea l s on o td i ﬀerent from
the control group patients. Our ﬁndings may be explainedGuldem Kilciler et al. 5
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Figure 2: Serial concentrations of IL-2, IL-4, TNF and IL-6 before and within 24 hours after ERCP in the patients (a) with post-ERCP
pancreatits and (b) without pancreatitis. Bars represent mean ± 95% CI. The diﬀerences between two groups were evaluated by Mann-
Whitney U test. P values were indicated above the boxes when a level of signiﬁcance less than or equal to .05 was reached in comparisons of
study groups.
by CRP being a late marker in the laboratory monitoring
of post-ERCP pancreatitis [18]. Its changes are commonly
initiated at least 24 hours after ERCP [4]. However, we did
not investigate the changes of CRP levels in the late phase
after ERCP. Therefore, our results showed that CRP does not
increase in the early phase after ERCP.
There are several speculative conclusions related to
cytokine investigations in ERCP in the literature. Our study6 Clinical and Developmental Immunology
provides a new insight in ERCP-induced pancreatitis with
regard to results. We found that the levels of TNFα were in-
creased at 12 hours after ERCP in the patients with post-
ERCP pancreatitis compared with those of the patients
without pancreatitis. There was no signiﬁcant diﬀerence in
TNFα concentrations before and 24 hours after ERCP bet-
ween complicated and uncomplicated patients. In Chen et
al.’sstudy,TNFαwasfoundsigniﬁcantlyincreasedat8and24
hoursafterERCPinthepatientswithpost-ERCPpancreatitis
[2]. However, Messmann et al. did not ﬁnd signiﬁcant dif-
ference in the TNFα measurements of patients with post-
ERCP pancreatitis [19].
We found that the serum levels of IL-4 at 24 hours after
ERCPwerelowerinthepatientswithpost-ERCPpancreatitis
and control group patients than in those of the patients
without post-ERCP pancreatitis. It is well known that IL-4
p l a y sac r u c i a lr o l ei nT h 2 - c e l ld e v e l o p m e n t[ 9, 10]. Addi-
tionally, IL-4 has potent anti-inﬂammatory properties and
inhibits secretion of IL-1β and TNFα by monocytes. It may
be said that low level of IL-4 in the patients with post-
ERCP panceratitis and control patients causes the relative or
absolute dominance of inﬂammatory state. We investigated
the serum levels of inﬂammatory cytokines including IL-2,
TNFα, IL-6 and IL-2/IL-4, and TNFα/IL-4 ratios before
and after ERCP in order to identify the dominance of in-
ﬂammatory or anti-inﬂammatory state at diﬀerent time poi-
nts of ERCP. According to our results, neither IL-2 levels
nor IL-2/IL-4 ratios were diﬀerent from one another among
the patients who underwent ERCP and the control patients.
Although there is not any report on IL-2 levels in before and
after ERCP, increased sIL-2r levels was observed in a study in
the patients with acute panceratitis [20]. We did not also ﬁnd
any report investigating the relation between IL-4 and ERCP
in the literature. However, in Chen et al.’s study, the other
anti-inﬂammatory cytokine IL-10 was reported as a marker
with respect to reﬂect the severity of acute pancreatitis [21].
This study seems contrary to our study with regard to in-
dicating the dominance of an anti-inﬂammatory state after
ERCP.
In our study, the evidences suggested TNFα dominance
in the patients with post-ERCP pancreatitis were high levels
of TNFα at 12 hours after ERCP and high ratio of TNFα/IL-4
at12and24hoursafterERCP.ThelevelsofTNFαat12hours
after ERCP in the complicated patients were not diﬀerent
fromthecontrolpatients.Theseﬁndingsarecompatiblewith
the studies reported by Chen et al. [2]a n dD e v i ` ere et al.
[22]butcontraryto Oezcueruemez-Porschet al.’s study[23].
In the ﬁrst study, the levels of TNFα were reported to be
signiﬁcantly increased at 8 and 24 hours after ERCP in
the patients with post-ERCP pancreatitis [2]. The increased
TNFα levels in patients with post-ERCP pancreatitis were
also observed in Devi` e r ee t .a l . ’ ss t u d y .H o w e v e r ,T N F α levels
at any time of ERCP were not detectable in the patients with
evidenceofERCP-inducedpancreasdamage.Althoughsome
controversial results in the literature, our ﬁndings together
with Chen et. al.’s study suggest that there was a bias towards
increase of TNFα within 24 hours after ERCP.
I no u rs t u d y ,I L - 6l e v e l sa t2 4h o u r sa f t e rE R C Pi n
the patients with post-ERCP pancreatitis were not diﬀerent
from the control group patients but higher than those of
the patients without post-ERCP pancreatits. However IL-6
levels before and 12 hours after ERCP in both patients with
ERCP-induced pancreatitis and without pancreatitis were
not observed diﬀerently from each other. As compatible with
ourresults,inmanystudies,IL-6hasbeenreportedasagood
predictor for the development of pancreatitis after ERCP
[2, 4, 23, 24].
We observed that the serial changes occur in IL-4, TNFα,
and IL-6 after ERCP. According to our ﬁndings, TNFα and
IL-6 levels in the complicated patients were found to be
incerased at 12 hours after ERCP compared to those of the
basal levels. In the complicated patients, IL-6 levels at 24
hours after ERCP were also higher than those of the basal
levels. Besides the increased levels of TNFα and IL-6 at 12
and 24 hours after ERCP were found in our uncomplicated
patients compared to those of the basal levels, the levels
of IL-4 were also found increased at 24 hours after ERCP
than those of the basal levels. Our results related to the
serial measurements of the cytokines support the existance
of inﬂammatory activity and subclinical pancreatic damage
in patients without ERCP-induced pancreatitis. Our ﬁndings
with respect to serial IL-6 changes are compatible with the
studies reported by Chen et al. [2] and Messmann et al. [19].
In their studies, maximal concentration of IL-6 in the ERCP
procedure was found 24 hours after ERCP.
We observed reasonable correlations among the mea-
sured parameters in the patients with or without ERCP-
induced pancreatitis. CRP was negatively correlated with
IL-4 levels at 24 hours after ERCP in the patients with
post-ERCP pancreatitis that supports the dominance of
inﬂammatory activity at this time after ERCP. Surprisingly,
basal IL-6 levels in the patients with post-ERCP pancreatitis
positively correlated with basal CRP levels, but negatively
correlated with basal IL-4 levels. On the other hand, IL-4
positively correlated with TNFα at 24 hours after ERCP
in the uncomplicated patients, but negatively correlated
with IL-6 at 12 hours after ERCP. These ﬁndings indirectly
support the existance of systemic immune activation in
the patients without ERCP-induced pancreatitis. Diﬀrerent
results related to the correlations among the cytokines, pan-
creatic enzymes, and CRP levels in the ERCP procedure were
reported in the literature. In the Chen et al.’s study, serum
IL-6 was found signiﬁcantly correlated with serum amylase
at 8 and 24 hours after ERCP [2]. In another study, serum
matrix metalloproteinase 9 (MMP9) level in severe acute
pancreatitis was positively correlated with TNFα and CRP
levels [25].
5. CONCLUSIONS
In conclusion, the enhancement of serum TNFα and IL-6
levels in the patients with ERCP-induced pancreatitis reﬂects
theinﬂammatoryactivity.Additionally,IL-4,IL-6,andTNFα
can be used in clinical laboratory monitoring of ERCP.
However, it should be considered that the Th1 or Th2 cy-
tokine dominance before and after ERCP is one of the
main factors determining the balance between pro- and
anti-inﬂammatory statuses of organism. Some conﬂictingGuldem Kilciler et al. 7
cytokine results about ERCP-induced pancreatitis in the
literature may depend on the direction of Th polarization
at the sampling time for serum cytokine levels. Therefore,
the other Th cytokines (IFNγ, IL-12, IL-18, IL-5, IL-13) may
inﬂuence the inﬂammatory activity after ERCP, and can be
a topic of the future study. In addition, it seems that the
presentingthecytokine proﬁleisimportanttoeﬀectiveusage
of anti-inﬂammatory cytokines and cytokine inhibitors in
ERCP-induced pancreatitis. On the other hand, monitoring
interval in the post-ERCP period should be longer than 24
hours.
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